SCHEMBL6694977

SCHEMBL6694977

COc1ccc(Oc2c(Cl)c(F)nc(F)c2Cl)cc1Oc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ HTT P42858 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ TTR P02766 3/20 0.42
▸ NPBWR1 P48145 3/20 0.40
▸ PTGES O14684 1/20 0.39
▸ BCHE P06276 5/20 0.37
▸ ACHE P22303 5/20 0.37
▸ GRIN1 Q05586 4/20 0.37
▸ GRIN2A Q12879 4/20 0.37
▸ GRIN2B Q13224 4/20 0.37
▸ LRRK2 Q5S007 1/20 0.37
▸ MCHR1 Q99705 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ PDGFRA P16234 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6689854 0.82 L3MBTL1 (0.39) L3MBTL1HTTTTRNPBWR1MEN1
SCHEMBL6692393 0.81 THRB (0.39) ALDH1A1NPBWR1MCHR1MEN1KMT2A
SCHEMBL6694189 0.80 TUBB1 (0.54) ALDH1A1MEN1KMT2A
SCHEMBL6691486 0.78 ALDH1A1 (0.48) L3MBTL1ALDH1A1NPBWR1MCHR1MEN1
SCHEMBL6693009 0.78 KDM4E (0.49) HTTALDH1A1MAPK1MEN1KMT2A
SCHEMBL2099937 0.78 ALDH1A1 (0.63) L3MBTL1HTTALDH1A1MAPK1TTR
SCHEMBL6694690 0.77 RORC (0.56) —
SCHEMBL6693303 0.76 TUBB1 (0.46) L3MBTL1ALDH1A1NPBWR1HTR2A
SCHEMBL7263203 0.75 PDGFRA (0.50) L3MBTL1HTTALDH1A1MAPK1TTR
SCHEMBL11015595 0.75 CA12 (0.65) L3MBTL1HTTALDH1A1MAPK1TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747048-B2 TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, BRISTOL-MYERS SQUIBB COMPANY 2004-06-08 — — US disclosed
US-20040039028-A1 Pyridine-based thyroid receptor ligands BRISTOL-MYERS SQUIBB COMPANY 2004-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039028-A1 Pyridine-based thyroid receptor ligands TSHR, THRB, THRA L3MBTL1 1162/4885HTT 4269/4885ALDH1A1 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback